ATE175442T1 - Therapie des zentralnervensystems mit genetisch modifizierten zellen - Google Patents

Therapie des zentralnervensystems mit genetisch modifizierten zellen

Info

Publication number
ATE175442T1
ATE175442T1 AT92925278T AT92925278T ATE175442T1 AT E175442 T1 ATE175442 T1 AT E175442T1 AT 92925278 T AT92925278 T AT 92925278T AT 92925278 T AT92925278 T AT 92925278T AT E175442 T1 ATE175442 T1 AT E175442T1
Authority
AT
Austria
Prior art keywords
nervous system
central nervous
therapy
genetically modified
modified cells
Prior art date
Application number
AT92925278T
Other languages
English (en)
Inventor
Fred Gage
Theodore Friedmann
Michael B Rosenberg
Jon A Wolff
Malcolm Schinstine
Michael D Kawaja
Jasodhara Ray
Original Assignee
Univ California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California filed Critical Univ California
Application granted granted Critical
Publication of ATE175442T1 publication Critical patent/ATE175442T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/33—Fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1025—Acyltransferases (2.3)
    • C12N9/1029—Acyltransferases (2.3) transferring groups other than amino-acyl groups (2.3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/16—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with reduced pteridine as one donor, and incorporation of one atom of oxygen (1.14.16)
    • C12Y114/16002—Tyrosine 3-monooxygenase (1.14.16.2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT92925278T 1991-11-15 1992-11-13 Therapie des zentralnervensystems mit genetisch modifizierten zellen ATE175442T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79289491A 1991-11-15 1991-11-15
CA002095300A CA2095300C (en) 1991-11-15 1993-04-30 Use of genetically modified cells to treat defects, disease or damage of the central nervous system
JP5136554A JPH06329559A (ja) 1991-11-15 1993-05-14 遺伝子的に修飾された細胞を移植して中枢神経系における欠陥、疾病、あるいは損傷を治療するための方法

Publications (1)

Publication Number Publication Date
ATE175442T1 true ATE175442T1 (de) 1999-01-15

Family

ID=27169416

Family Applications (1)

Application Number Title Priority Date Filing Date
AT92925278T ATE175442T1 (de) 1991-11-15 1992-11-13 Therapie des zentralnervensystems mit genetisch modifizierten zellen

Country Status (9)

Country Link
EP (1) EP0625195B1 (de)
JP (1) JPH06329559A (de)
AT (1) ATE175442T1 (de)
CA (1) CA2095300C (de)
DE (1) DE69228127T2 (de)
DK (1) DK0625195T3 (de)
ES (1) ES2126606T3 (de)
GR (1) GR3029362T3 (de)
WO (1) WO1993010234A1 (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6103226A (en) * 1994-08-12 2000-08-15 Arch Development Corporation Genetically engineered cells that produce produce L. Dopa
US6294383B1 (en) 1994-11-08 2001-09-25 The Mclean Hospital Corporation Porcine neural cells and their use in treatment of neurological deficits due to neurodegenerative diseases
US6204053B1 (en) 1994-11-08 2001-03-20 Diacrin, Inc. Porcine cortical cells and their use in treatment of neurological deficits due to neurodegenerative diseases
CA2210718A1 (en) 1995-01-17 1996-07-25 Genetic Therapy, Inc. Delivery of therapeutic agents by gene therapy
US5753505A (en) * 1995-07-06 1998-05-19 Emory University Neuronal progenitor cells and uses thereof
CA2245224A1 (en) 1998-08-14 2000-02-14 Jiang-Hong Giong Chemokine receptor antagonists and chemotherapeutics
JP2002506830A (ja) 1998-03-13 2002-03-05 ザ ユニバーシティ オブ ブリティッシュ コロンビア 治療的ケモカイン受容体アンタゴニスト
CA2305787A1 (en) 2000-05-09 2001-11-09 The University Of British Columbia Cxcr4 antagonist treatment of hematopoietic cells
US6444205B2 (en) 1998-09-30 2002-09-03 Diacrin, Inc. Transplantation of neural cells for the treatment of chronic pain or spasticity
US20040120891A1 (en) 1998-12-21 2004-06-24 Craig Hill Compounds for intracellular delivery of therapeutic moieties to nerve cells
US6652864B1 (en) 1998-12-21 2003-11-25 Asilomar Pharmaceuticals, Inc. Compounds for intracellular delivery of therapeutic moieties to nerve cells
NZ514620A (en) * 1999-03-04 2004-04-30 Ppl Therapeutics Scotland Ltd Genetic modification of somatic cells and uses thereof
WO2001075094A1 (en) * 2000-04-04 2001-10-11 Thomas Jefferson University Application of myeloid-origin cells to the nervous system
US7378098B2 (en) 2000-04-12 2008-05-27 The University Of British Columbia CXC chemokine receptor 4 agonist peptides
US20050059584A1 (en) 2002-08-16 2005-03-17 Ahmed Merzouk Novel chemokine mimetics synthesis and their use
US7368425B2 (en) 2006-03-24 2008-05-06 Chemokine Therapeutics Corp. Cyclic peptides for modulating growth of neo-vessels and their use in therapeutic angiogenesis
US20030124095A1 (en) 2001-12-31 2003-07-03 Regents Of The University Of California Methods for therapeutic use of brain derived neurotrophic factor in the entorhinal cortex
KR101226702B1 (ko) * 2010-10-08 2013-01-25 충북대학교 산학협력단 인간 콜린 아세틸트랜스퍼라아제를 발현하는 인간 신경줄기세포 및 이의 용도
CA3105879A1 (en) 2018-07-18 2020-01-23 Manzanita Pharmaceuticals, Inc. Conjugates for delivering an anti-cancer agent to nerve cells, methods of use and methods of making thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE117375T1 (de) * 1987-09-11 1995-02-15 Whitehead Biomedical Inst Transduktionsveränderte fibroblasten und ihre anwendung.
US5082670A (en) * 1988-12-15 1992-01-21 The Regents Of The University Of California Method of grafting genetically modified cells to treat defects, disease or damage or the central nervous system
US6511823B1 (en) * 1990-08-20 2003-01-28 American Cyanamid Corporation Heparin binding neurotrophic factor gene sequence
WO1992009688A1 (en) * 1990-11-21 1992-06-11 Massachusetts Institute Of Technology MICE HAVING β2 MICROGLOBULIN GENE DISRUPTION

Also Published As

Publication number Publication date
EP0625195A1 (de) 1994-11-23
DK0625195T3 (da) 1999-08-30
DE69228127T2 (de) 1999-09-02
DE69228127D1 (de) 1999-02-18
CA2095300C (en) 2002-06-25
CA2095300A1 (en) 1994-10-31
EP0625195B1 (de) 1999-01-07
ES2126606T3 (es) 1999-04-01
WO1993010234A1 (en) 1993-05-27
JPH06329559A (ja) 1994-11-29
GR3029362T3 (en) 1999-05-28

Similar Documents

Publication Publication Date Title
ATE175442T1 (de) Therapie des zentralnervensystems mit genetisch modifizierten zellen
DE68929077D1 (de) Transplantieren von genetisch modifizierten zellen zur behandlung von krankheiten des zentralen nervensystems
PT923293E (pt) Tratamento da diarreia
FI844510L (fi) Ensym-resistenta immunsystemet modulerande peptider.
DK0918848T3 (da) Fremgangsmåder til at behandle kræftsygdomme og patogene infektioner ved anvendelse af antigenpræsenterende celler påfyldt med RNA
GB2136814B (en) Dna vectors
CA2265464A1 (en) Therapy for .alpha.-galactosidase a deficiency
FI971116A7 (fi) Fotodynaaminen terapia selektiivisessä solujen inaktivoinnissa veressä sekä immuunijärjestelmän häiriötautien hoito
ATE211467T1 (de) 4-amino-derivate der mycophenolsäure mit immun suppressiver wirkung
ATE310077T1 (de) Erzeugung von hämatopoietischen zellen aus multipotenten neuronalen stammzellen
EP0653491A4 (de) Verfahren zum einbringen fremder dns in zellen.
ES2133714T3 (es) Compuestos heterociclicos para el tratamiento de trastornos del snc y cardiovasculares.
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
ATE122720T1 (de) Virales vektorsystem zum einführen fremder dns- expressionserzeugnisse in gallinaceenvögeln.
BR8100869A (pt) Processo para o isolamento de substancia solida de caldo de cultura de salinomicina e substancia solida de caldo de cultura de salinomicina
NO178870C (no) Fremgangsmåte for fremstilling av modifisert Eglin B eller C samt DNA, ekspresjonsvektor og vertsmikroorganisme
NZ335534A (en) Method of identifying potential pharmaceuticals from plant extracts
GR3003950T3 (de)
RU96102282A (ru) Способ терапии поллиноза
NO900044L (no) Hemorroidale, andre blandinger og metoder for behandling.
JPS6464672A (en) Impact medical treatment device
ES1022266U (es) Suspension simple para cables conductores

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee